News Sentiment

ABEO sentiment intelligence

Abeona Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 48 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.98 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 40

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+9.1% over one week, +26.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Precision Trading with Abeona Therapeutics Inc. (ABEO) Risk Zones

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction 9.1% Price confirming higher
Trend fit Trend active 26.2% over four weeks
Fair value 29.6% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 35
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 40
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 7
TradingView 7
Investing.com 6
simplywall.st 5
Stock Traders Daily 2
Investing.com South Africa 1
Investing.com Nigeria 1

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 15
Guidance 2
Regulatory and legal 2
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 48
Stock Traders Daily Direct company coverage

Precision Trading with Abeona Therapeutics Inc. (ABEO) Risk Zones

This article analyzes Abeona Therapeutics Inc. (ABEO) using AI models to provide trading strategies based on different risk profiles and holding periods. It identifies strong near and mid-term sentiment but a weak long-term outlook for ABEO, with no resistance levels identified a

Tone
Positive 75/100
Event
Guidance
Published
13 Jul 2026 02:41
Source
Stock Traders Daily
Stock Titan Direct company coverage

Abeona Therapeutics (NASDAQ: ABEO) shifts 760,870 warrants to SILV Fund

Abeona Therapeutics (NASDAQ: ABEO) has filed a prospectus supplement to update a previous resale registration, indicating the assignment of 760,870 Common Warrants from Point72 Associates, LLC to SILV Fund, Ltd. This update does not change the total number of registered shares fo

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

Tax-related stock sale by Abeona (ABEO) CEO leaves 1.31M shares

Abeona Therapeutics Inc. CEO Vishwas Seshadri sold 67,971 shares of common stock at a weighted average price of $6.9637 per share to cover tax obligations from vesting restricted stock awards. Following this transaction, Seshadri still holds 1,306,108 shares of ABEO. The sale was

Tone
Negative 40/100
Event
Market update
Published
10 Jul 2026 12:09
Source
Stock Titan
Investing.com Direct company coverage

Abeona Therapeutics CCO Vasanthavada Madhav sells $87,784 in stock

Vasanthavada Madhav, CCO of Abeona Therapeutics (NASDAQ:ABEO), sold 12,606 shares totaling $87,784 on July 9, 2026. This sale helps cover tax obligations from stock awards, leaving Madhav with 290,623 shares. The company's stock has seen a significant 37% gain over the past six m

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 11:39
Source
Investing.com
Stock Titan Direct company coverage

Abeona (ABEO) CFO sells 24,880 shares to cover taxes on vested stock

Abeona Therapeutics Inc.'s Chief Financial Officer, Joseph Walter Vazzano, sold 24,880 shares of common stock at a weighted average price of $6.9637 per share to cover tax obligations from vested restricted stock awards. Following this transaction, Vazzano directly holds 493,557

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 11:39
Source
Stock Titan
Stock Titan Direct company coverage

Abeona Therapeutics (ABEO) CCO sells 12,606 shares, retains 290,623

Abeona Therapeutics' Chief Commercial Officer, Madhav Vasanthavada, sold 12,606 shares of common stock at a weighted average price of $6.9637 per share. This open-market transaction represents a small portion of his holdings, as he retains 290,623 shares after the sale. The sale

Tone
Negative 37/100
Event
Market update
Published
10 Jul 2026 11:39
Source
Stock Titan
Investing.com Direct company coverage

Brendan O’Malley sells $83,912 in Abeona Therapeutics stock

Brendan M. O’Malley, Senior Vice President and Chief Legal Officer of Abeona Therapeutics (NASDAQ:ABEO), sold 12,050 shares totaling $83,912 to cover tax obligations from restricted stock awards. Following this transaction, O'Malley still holds 427,953 shares. The company recentl

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 00:39
Source
Investing.com
Investing.com Nigeria Direct company coverage

Form 4 Abeona Therapeutics Inc For: 9 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Abeona Therapeutics Inc. for July 9th. Form 4 filings are regulatory documents that disclose changes in stock ownership by company insiders. The brief news item includes the company's stock symbol (ABEO) and its perfo

Tone
Neutral 50/100
Event
Regulatory and legal
Published
10 Jul 2026 00:26
Source
Investing.com Nigeria
Investing.com Direct company coverage

Abeona Therapeutics CFO Vazzano sells $173,256 in common stock

Abeona Therapeutics CFO Joseph Walter Vazzano sold 24,880 shares of the company's common stock for a total of $173,256, at an average price of $6.9637 per share. This sale was conducted to cover tax obligations from vested restricted stock awards. Following the transaction, Vazza

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 23:39
Source
Investing.com
Stock Titan Direct company coverage

Abeona Therapeutics (ABEO) SVP sells shares to cover tax obligations

Brendan M. O'Malley, SVP and Chief Legal Officer of Abeona Therapeutics (ABEO), sold 12,050 shares of common stock at a weighted average price of $6.9637 per share to cover tax obligations from vested restricted stock awards. Following the sale, O'Malley retains 427,953 shares in

Tone
Negative 39/100
Event
Market update
Published
09 Jul 2026 23:39
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 144 ABEONA THERAPEUTICS INC. For: 9 July By Investing.com

This article announces the filing of Form 144 for ABEONA THERAPEUTICS INC. on July 9. The report is from Investing.com and was published in the Stock Market section. The form filing indicates potential insider transactions or sales of restricted securities.

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:14
Source
Investing.com Canada
Stock Titan Direct company coverage

ABEO (NASDAQ) Form 144 shows 141,333 restricted shares planned for sale

ABEO (Abeona Therapeutics Inc.) filed a Form 144 notice indicating a planned sale of 141,333 Restricted Stock Awards on July 8, 2026. The filing also reports prior sales by Vishwas Seshadri, totaling 56,344 shares in early June 2026, with recorded dollar values. This routine regu

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:14
Source
Stock Titan
Stock Titan Direct company coverage

Insider share sales and RSAs reported by ABEO (NASDAQ: ABEO)

ABEO (NASDAQ: ABEO) reported insider transactions via a Form 144 disclosure, indicating sales of Common Stock by Madhav Vasanthavada across May and June 2026. The filing also detailed an equity compensation entry of 28,519 Restricted Stock Awards dated July 8, 2026, and stated 56

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:14
Source
Stock Titan
Stock Titan Direct company coverage

ABEO (NASDAQ: ABEO) director reports proposed stock sales in Form 144

A director of ABEO (NASDAQ: ABEO) has filed a Form 144, disclosing proposed sales of common stock. The filing details a restricted stock award of 51,733 shares on July 8, 2026, and previous proposed sales of 10,271 shares on June 8, 2026, and 39,067 shares on June 9, 2026, with a

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:14
Source
Stock Titan
Stock Titan Direct company coverage

ABEO (Nasdaq: ABEO) files Form 144: 34,230 restricted shares; insider sales noted

Abeona Therapeutics Inc. (ABEO) has filed a Form 144, indicating proposed sales of common stock and recent restricted stock awards. The filing specifies 34,230 restricted shares dated July 8, 2026, and notes insider sales by Brendan O'Malley of 4,826 shares on June 8, 2026, and 6

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:14
Source
Stock Titan
Stock Titan Direct company coverage

ABEO (NASDAQ: ABEO) Rule 144 sale notice — 18,160 shares

Abeona Therapeutics Inc. (NASDAQ: ABEO) filed a Rule 144 notice, reporting a sale of 18,160 shares of common stock on June 15, 2026, for total proceeds of $103,695.00. The shares sold trace back to an equity compensation grant on May 20, 2020. The company's outstanding common sto

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 20:40
Source
Stock Titan
TradingView Direct company coverage

Price to sales forward of Abeona Therapeutics Inc. – NASDAQ:ABEO

This article provides a financial overview of Abeona Therapeutics Inc. (NASDAQ: ABEO), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or data-point article from TradingView, offering financial metrics for the company. The content includes navig

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 22:13
Source
TradingView
Stock Titan Direct company coverage

Abeona Therapeutics (ABEO) director Alland Leila sells 11,000 shares

Abeona Therapeutics director Alland Leila reported an open-market sale of 11,000 shares of company common stock at a weighted average price of $5.917 per share. The sale occurred on June 30, 2026, through multiple transactions. Following this sale, Leila directly holds 162,614 sh

Tone
Negative 33/100
Event
Market update
Published
02 Jul 2026 20:10
Source
Stock Titan
Finviz Direct company coverage

ABEO - Abeona Therapeutics Inc Latest SEC Filings

This article provides the latest SEC filings and comprehensive financial statistics for Abeona Therapeutics Inc. (ABEO). It includes details on market performance, key financial ratios, insider and institutional ownership, analyst ratings, and various stock performance metrics.

Tone
Neutral 50/100
Event
Analyst action
Published
02 Jul 2026 12:09
Source
Finviz
Stock Traders Daily Direct company coverage

Technical Reactions to ABEO Trends in Macro Strategies

Abeona Therapeutics Inc. (NASDAQ: ABEO) is showing strong near and mid-term sentiment but a weak long-term outlook, with no clear price positioning signal identified. Quantitative AI models have generated distinct trading strategies, including position, momentum breakout, and ris

Tone
Positive 66/100
Event
Guidance
Published
02 Jul 2026 01:16
Source
Stock Traders Daily
Market source Direct company coverage

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics Inc. announced new equity awards granted to five non-executive employees as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). These restricted stock awards, totaling up to 9,000 shares, will vest over three years. Abeona Therapeut

Tone
Positive 60/100
Event
Market update
Published
01 Jul 2026 21:39
Source
Market source
Stock Titan Direct company coverage

Abeona gives 5 new hires restricted stock worth 9,000 shares

Abeona Therapeutics (Nasdaq: ABEO) has granted equity awards to five new non-executive employees, totaling up to 9,000 restricted shares. These awards serve as a material inducement for employment and will vest in three equal annual installments over three years, contingent on co

Tone
Positive 71/100
Event
Market update
Published
01 Jul 2026 11:40
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to revenue forward of Abeona Therapeutics Inc. – NASDAQ:ABEO

This article displays the enterprise value to revenue forward for Abeona Therapeutics Inc. (NASDAQ: ABEO). It provides financial data and is presented on the TradingView platform, an interface for market analysis.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 13:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Abeona Therapeutics, Inc. – HAM:PCJ

This article provides financial information for Abeona Therapeutics, Inc. (PCJ) on the Hamburg Stock Exchange, specifically focusing on its forward price-to-sales ratio. It appears to be a basic financial data display from TradingView, offering an overview of the company's financ

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 08:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Abeona Therapeutics Inc. – NASDAQ:ABEO

The article focuses on the "Enterprise value to EBITDA forward" metric for Abeona Therapeutics Inc. (NASDAQ: ABEO). It appears to be a financial data page from TradingView, providing an overview of this specific financial ratio for the company's stock.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 04:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Abeona Therapeutics, Inc. – HAM:PCJ

This article provides the "Price to earnings forward" metric for Abeona Therapeutics, Inc. (HAM:PCJ) on the Hamburg Stock Exchange. The data is presented within a TradingView context, indicating a financial overview for the pharmaceutical company. The market was closed at the tim

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 13:41
Source
TradingView